Teijin Pharma Limited announced the European launch of TMX-67 (febuxostat), a novel drug discovered by Teijin Pharma for the treatment of hyperuricemia in patients with gout. Ipsen, a global biotechnology specialty care group and the TMX-67 licensee in Europe, and its sublicensee the Menarini Group, the first Italian pharmaceutical group in the world, have began marketing the product in Europe under the brand name ADENURIC(r).
ADENURIC(r) will be further launched by Menarini, which holds the marketing rights in 41 European countries, in the U.K. on March 11, Germany on March 15 and Ireland on March 29. Additional launches in other European countries are expected.
In July 2003, Teijin Pharma signed an exclusive license agreement with Ipsen for the development and marketing of TMX-67 in Europe. Following EMEA approval in April 2008, Ipsen signed in October 2009 an exclusive sublicense agreement with Menarini, which is Italy's largest pharmaceutical company and has the fourth-largest pharmaceutical team for delivering medical information to physicians.
TMX-67, one of Teijin Pharma's most promising products, has strong global potential. Approval was obtained by licensees, Takeda Pharmaceuticals North America in the United States in February 2009 and SK Chemicals in Korea in June 2009. Sales are already underway in the United States. In addition, Teijin Pharma signed in May 2009 an exclusive distributorship agreement with Astellas Pharma Taiwan, its licensee for the Taiwanese market, and resubmitted a New Drug Application (NDA) in Japan in December 2009. Teijin Pharma will continue to pursue collaborative efforts to broaden TMX-67's global availability. The goal is to reach global annual sales of roughly 100 billion yen, including 40-60 billion yen from Europe in the foreseeable future.
Gout, a chronic disease marked by gouty arthritis associated with severe pain, is mainly treated with medication that inhibits xanthine oxidase, an enzyme directly related to the production of uric acid. The current leading medication, allopurinol, was developed nearly 40 years ago, so a new drug that provides more options for the treatment of gout and hyperuricemia has long been sought.
TMX-67, developed by Teijin Pharma after intensive research, is an oral, once-daily, highly potent, non-purine selective inhibitor of xanthine oxidase. A novel drug with a structure completely different from that of allopurinol, TMX-67 lowers the level of uric acid in the blood of hyperuricemic patients suffering from gout. TMX-67 has proven therapeutic superiority to allopurinol and above all is well tolerated by patients suffering from a mild and moderate renal impairment.
About ADENURIC(r)
Product name: ADENURIC(r)
Generic name: febuxostat
Pharmaceutical Forms and Strength: film-coated tablets, 80mg and 120mg
Therapeutic Indications: Treatment of chronic hyperuricemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis)
Dosage and Administration: 80 mg once daily without regard to food. If serum uric acid is >6 mg/dl after 2-4 weeks, 120mg once daily may be considered
About Teijin Pharma Limited
Teijin Pharma Limited, the core company of Teijin Group's medical and pharmaceuticals business, focuses on three key therapeutic areas: respiratory, bone/joint, and cardiovascular/metabolic diseases. Teijin Pharma has strong marketing positions, particularly in the respiratory and bone/joint areas, with pharmaceutical products as well as a home healthcare business, including home oxygen therapy. Teijin Pharma continues to enhance its presence worldwide through in-house R&D as well as in-licensing and out-licensing activities.
For more information, visit www.teijin-pharma.co.jp/english/index.html
About the Teijin Group
Based in Tokyo and Osaka, Japan, Teijin is a global technology-driven group operating in five main fields: synthetic fibers (polyester fibers, carbon fibers and aramid fibers); films and plastics; pharmaceuticals and home health care; trading and retail; and IT and new products. Teijin Limited, the holding company for the Teijin Group, is listed on the Tokyo and Osaka stock exchanges. The group had consolidated sales of USD 10.5 billion (JPY 943.4 billion, USD 1=JPY 90) in fiscal 2008 and employs 19,453 people worldwide, with 169 companies around the world. Please visit www.teijin.co.jp/english
Business & Industry
- AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson's disease
- Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
- Bayer and Aignostics to collaborate on next generation precision oncology
- AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline
- European Commission approves Pfizer's PREVENAR 20® to help protect infants and children against pneumococcal disease
Research & Development
- Researchers develop a new way to safely boost immune cells to fight cancer
- How the Birmingham Drug Discovery Hub created an investment-ready 'drug library'
- Common HIV treatments may aid Alzheimer's disease patients
- Next-generation treatments hitch a ride into cancer cells
- Groundbreaking treatment approach shows promise in hard-to-treat cancers
- This outdated diabetes drug still has something to offer
- New drug prevents flu-related inflammation and lung damage
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy
- FDA approves first gene therapies to treat patients with sickle cell disease
- FDA approves first therapy for rare type of non-cancerous tumors
- First electronic product information (ePI) published for selected human medicines
- FDA approves first treatment for patients with rare inherited blood clotting disorder